News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xigen S.A., Swiss Developer of Therapeutic Peptides, Raises $20 Million in Series B Funding



11/20/2009 7:54:55 AM

Bookmark and Share

Pehub.com -- Xigen, a Swiss biopharmaceutical company developing innovative cell-penetrating peptides with high stability and specificity for a broad range of therapeutic indications, announced today the completion earlier this year of a Series B financing round in which it raised USD 20 million (CHF 20 million) from existing investor Tilocor Life Science.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES